tiprankstipranks

Dianthus price target lowered to $36 from $38 at Wedbush

Wedbush lowered the firm’s price target on Dianthus to $36 from $38 and keeps an Outperform rating on the shares. Most importantly in the company’s Q2 results, it was announced all development timelines remain on track, the analyst tells investors. The firm’s DNTH103 estimates remain unchanged and assume the earliest potential launch in FY28. The firm is also increasing its research and development expense ramp from FY24 forward to reflect the accelerating clinical trial efforts.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue